Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study. 1981

P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap

A phase I clinical study of a combination of thymidine (TdR), inosine (IR), and allopurinol used as rescue from 24-hour infusions of methotrexate (MTX) was undertaken following animal studies that had shown a better preservation of antitumor activity with this system than with folinic acid. TdR and IR were given in the dose ratio 5:1 by weight throughout. Rescue from MTX, 400 mg/m2, could be achieved with a TdR dose in the combination of 1 g/m2/24 hours. This same rescue was also effective when the MTX dose was increased to 800 mg/m2, but only partly effective at an MTX dose of 1.5 g/m2. It was not necessary to raise the levels of circulating nucleosides significantly above normal to achieve rescue. MTX-related skin lesions occurred more frequently than might be expected with the MTX dose used.

UI MeSH Term Description Entries
D007042 Hypoxanthines Purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism.
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D007288 Inosine A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland, 28th ed)
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
March 1984, Cancer treatment reports,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
November 1982, Cancer research,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
August 1991, Investigational new drugs,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
February 1992, Transplantation,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
February 1978, Cancer research,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
March 1978, Cancer treatment reports,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
March 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
March 1980, Cancer,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
September 1978, Cancer treatment reports,
P J Dady, and G A Taylor, and J F Muindi, and A H Calvert, and I E Smith, and J F Smyth, and K R Harrap
February 1979, Cancer treatment reports,
Copied contents to your clipboard!